BASIS OF PRESENTATION, SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share of common stock as of the periods presented, because to do so would be anti-dilutive, were as follows:


	December 31,
	2023	2022
Shares issuable upon exercise of stock options	7,523,947	5,610,893
Shares issuable upon conversion election for Term Loan	988,142	—
Shares issuable upon exercise of warrant	730,769	—
Unvested RSUs	328,500	—
Total	9,571,358	5,610,893

Schedule of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash from the balance sheets to the statements of cash flows (in thousands):


	December 31,
	2023		2022
Cash and cash equivalents	$	66,886	$	130,101
Restricted cash	233		—
Total cash, cash equivalents and restricted cash	$	67,119	$	130,101